Literature DB >> 30498933

Fatal combination of mitragynine and quetiapine - a case report with discussion of a potential herb-drug interaction.

Rhome L Hughes1.   

Abstract

Kratom is a plant with dose-dependent mixed stimulant and opioid properties whose pharmacologic characteristics and social impact continue to be described. The main active isolate of kratom is mitragynine, an indole-containing alkaloid with opioid-like effects. Kratom toxicity and kratom-associated fatalities have been described, including those in association with additional drugs. In this paper we describe the case of a 27-year-old man who was found deceased with a toxic blood concentration of quetiapine in conjunction with the qualitative presence of mitragynine. Investigative and autopsy findings suggested perimortem hyperthermia and seizure-like activity. Kratom toxicity and kratom-associated fatalities are being increasingly reported. Experiments with kratom extracts have shown inhibitory effects upon hepatic CYP enzymes, leading to previous speculation of the potential for clinically significant interactions between kratom and a wide array of medications. Herein is described a fatal case of quetiapine toxicity complicated by mitragynine use. The potential ability of mitragynine to alter the pharmacokinetics of a prescription medication via inhibition of its hepatic metabolism is discussed.

Entities:  

Keywords:  CYP; Kratom; Mitragynine; Overdose; Quetiapine

Mesh:

Substances:

Year:  2018        PMID: 30498933     DOI: 10.1007/s12024-018-0049-9

Source DB:  PubMed          Journal:  Forensic Sci Med Pathol        ISSN: 1547-769X            Impact factor:   2.007


  19 in total

1.  Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.

Authors:  Scott W Grimm; Neil M Richtand; Helen R Winter; Karen R Stams; Stots B Reele
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

Review 2.  A Case Report of Kratom Addiction and Withdrawal.

Authors:  David Galbis-Reig
Journal:  WMJ       Date:  2016-02

3.  Seizure and coma following Kratom (Mitragynina speciosa Korth) exposure.

Authors:  Jamie L Nelsen; Jeff Lapoint; Michael J Hodgman; Kenneth M Aldous
Journal:  J Med Toxicol       Date:  2010-12

Review 4.  Neuroleptic malignant syndrome secondary to quetiapine.

Authors:  Justine Schuller Gortney; Alexandria Fagan; Julie Cold Kissack
Journal:  Ann Pharmacother       Date:  2009-03-18       Impact factor: 3.154

Review 5.  Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects.

Authors:  Walter C Prozialeck; Jateen K Jivan; Shridhar V Andurkar
Journal:  J Am Osteopath Assoc       Date:  2012-12

6.  Loss of consciousness from acute quetiapine overdosage.

Authors:  T J Harmon; J G Benitez; E P Krenzelok; E Cortes-Belen
Journal:  J Toxicol Clin Toxicol       Date:  1998

7.  Posterior reversible leukoencephalopathy syndrome after kratom ingestion.

Authors:  Austin Castillo; J Drew Payne; Kenneth Nugent
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-07

8.  Pharmacokinetics of mitragynine in man.

Authors:  Satariya Trakulsrichai; Korbtham Sathirakul; Saranya Auparakkitanon; Jatupon Krongvorakul; Jetjamnong Sueajai; Nantida Noumjad; Chonlaphat Sukasem; Winai Wananukul
Journal:  Drug Des Devel Ther       Date:  2015-04-29       Impact factor: 4.162

9.  Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities.

Authors:  N A Hanapi; S Ismail; S M Mansor
Journal:  Pharmacognosy Res       Date:  2013-10

Review 10.  Hepatotoxicity Induced by "the 3Ks": Kava, Kratom and Khat.

Authors:  Flaminia Pantano; Roberta Tittarelli; Giulio Mannocchi; Simona Zaami; Serafino Ricci; Raffaele Giorgetti; Daniela Terranova; Francesco P Busardò; Enrico Marinelli
Journal:  Int J Mol Sci       Date:  2016-04-16       Impact factor: 5.923

View more
  8 in total

Review 1.  HDI Highlighter, The First Intelligent Tool to Screen the Literature on Herb-Drug Interactions.

Authors:  Anthony Cnudde; Patrick Watrin; Florence Souard
Journal:  Clin Pharmacokinet       Date:  2022-05-31       Impact factor: 5.577

Review 2.  Health Effects Associated With Kratom (Mitragyna speciosa) and Polysubstance Use: A Narrative Review.

Authors:  Catherine W Striley; Carolin C Hoeflich; Andrew T Viegas; Lindsey A Berkowitz; Emily G Matthews; Leyla P Akin; Chidinma Iheanyi-Okeahialam; Urmeen Mansoor; Christopher R McCurdy
Journal:  Subst Abuse       Date:  2022-05-20

3.  The inhibitory effects of mitragynine on P-glycoprotein in vitro.

Authors:  Noradliyanti Rusli; Azimah Amanah; Gurjeet Kaur; Mohd Ilham Adenan; Shaida Fariza Sulaiman; Habibah Abdul Wahab; Mei Lan Tan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-02       Impact factor: 3.000

Review 4.  Mitragyna speciosa: Clinical, Toxicological Aspects and Analysis in Biological and Non-Biological Samples.

Authors:  Vânia Meireles; Tiago Rosado; Mário Barroso; Sofia Soares; Joana Gonçalves; Ângelo Luís; Débora Caramelo; Ana Y Simão; Nicolás Fernández; Ana Paula Duarte; Eugenia Gallardo
Journal:  Medicines (Basel)       Date:  2019-03-04

Review 5.  Kratom-Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review.

Authors:  Steven C Eastlack; Elyse M Cornett; Alan D Kaye
Journal:  Pain Ther       Date:  2020-01-28

6.  Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant.

Authors:  Alessandro E Vento; Simone de Persis; Sergio De Filippis; Fabrizio Schifano; Flavia Napoletano; John M Corkery; Georgios D Kotzalidis
Journal:  Front Psychiatry       Date:  2021-03-31       Impact factor: 4.157

7.  Herb-anticancer drug interactions in real life based on VigiBase, the WHO global database.

Authors:  Stéphanie Pochet; Anne-Sophie Lechon; Cécile Lescrainier; Carine De Vriese; Véronique Mathieu; Jamila Hamdani; Florence Souard
Journal:  Sci Rep       Date:  2022-08-19       Impact factor: 4.996

8.  Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations.

Authors:  Rakshit S Tanna; Dan-Dan Tian; Nadja B Cech; Nicholas H Oberlies; Allan E Rettie; Kenneth E Thummel; Mary F Paine
Journal:  J Pharmacol Exp Ther       Date:  2020-10-22       Impact factor: 4.030

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.